2023年7月27日

筹资一年来,三Medicxi-backed创业公司被大型制药公司收购。7月27日,2023年出版欧洲生命科学投资公司股票通过盖蒂图片社Medicxi周四表示,筹集了4亿美元,成为最新一biotech-focused风险投资公司提高其资本储备今年迄今为止。该公司将使用新基金继续投资于生物技术公司则“以”,或公司专注于一个或两个实验药物而不是广泛的审计平台。这是第四个基金。最大的公司之一的在欧洲,Medicxi宣布新基金在其投资组合公司的几个。在过去的一年里,皮肤药物开发者维拉里疗法被Incyte收购,自身免疫性启动MiroBio卖给基列和减肥药启动Versanis生物被礼来。这些收购为该公司提供了一个快速的投资回报。例如,Medicxi与阿特拉斯公司和Aditum生物在2021年投资7000万美元到Versanis。生物技术被卖给礼来公司不到两年后的交易价值可能高达19亿美元。MiroBio和维拉里都成立于2019年,并于2023年获得。 “This new fund consolidates Medicxi’s position as a key operating platform for scientific entrepreneurs and drug hunters and is deliberately sized for our investment model,” Francesco De Rubertis, Medicxi’s co-founder, said in a statement. Previously known as Medicxi Ventures, the firm launched out of Index Ventures in 2016 with backing from GSK and Johnson & Johnson. Its portfolio includes a number of public companies, such as Centessa Pharmaceuticals , Molecular Partners and Minerva Biosciences. Others, such as Genmab and Phathom Pharmaceuticals , have successfully developed marketed medicines. Medicxi joins other biotech investors, such as Westlake Village Biopartners and SR One , in closing new funds this year. New firms, such as Dimension and Cure Ventures , have also raked in hundreds of millions of dollars to support young biotech companies. Overall, venture firms raised approximately $163 billion in 2022, and invested nearly $31 billion into biotech and pharma companies last year, according to the National Venture Capital Association .